NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

COMMON STOCK WARRANTS (Details Narrative)

COMMON STOCK WARRANTS (Details Narrative) (USD $)	0 Months Ended		3 Months Ended	6 Months Ended		66 Months Ended		0 Months Ended																																		1 Months Ended	6 Months Ended		6 Months Ended
COMMON STOCK WARRANTS (Details Narrative) (USD $)	Apr. 05, 2013	Mar. 27, 2013	Mar. 31, 2013	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Oct. 30, 2012	Mar. 31, 2013 Warrants	Mar. 27, 2013 Warrants	Mar. 23, 2013 Warrants	Mar. 21, 2013 Warrants	Mar. 31, 2013 Warrants	Mar. 11, 2013 Warrants	Mar. 07, 2013 Warrants	Oct. 30, 2012 Warrants	Oct. 24, 2012 Warrants	Sep. 07, 2012 Warrants	Jul. 17, 2012 Warrants	Jul. 11, 2012 Warrants	Jun. 28, 2012 Warrants	May 18, 2012 Warrants	Apr. 12, 2012 Warrants	Apr. 10, 2012 Warrants	Mar. 03, 2012 Warrants	Dec. 21, 2011 Warrants	Dec. 16, 2011 Warrants	Aug. 23, 2011 Warrants	Jul. 15, 2011 Warrants	Jun. 13, 2011 Warrants	May 12, 2011 Warrants	Dec. 30, 2010 Warrants	Jul. 23, 2010 Warrants	Apr. 09, 2010 Warrants	Jan. 15, 2010 Warrants	Dec. 15, 2009 Warrants	Dec. 04, 2009 Warrants	Nov. 09, 2009 Warrants	Oct. 09, 2009 Warrants	Sep. 30, 2009 Warrants	Jun. 03, 2009 Warrants	Mar. 20, 2009 Warrants	Mar. 31, 2013 Warrants	Mar. 31, 2013 Warrants	Dec. 31, 2012 Warrants	Mar. 31, 2013 Warrants Lower Range	Mar. 31, 2013 Warrants Upper Range
Exercise of awards, shares	4,244,984	237,420						109,136	(2,520,000)	(11,111)			(5,037)	(20,988)		(200,000)		(30,000)					(43,392)												(5,583,336)							2,757,136	20,988
Stock price at valuation																																													$ 0.21	$ 1.44
Expected term																																													3 years	5 years
Exercise Price																																													$ 0.50	$ 1.44
Risk free interest rate																																													0.21%	2.90%
Dividend yield																																											0.00%
Volatility rate																																													114.00%	276.00%
Extension of warrants, description															On October 30, 2012, the Company agreed to extend the term of the 11,985,367 common stock purchase warrants, expiring October 31, 2012, to April 30, 2013, subject to the warrant agreement, as amended. These amendments include removal of the cashless exercise provision and early termination of the extension period, at the sole discretion of the Company, in the event that the Company's common stock trades at or above $1.50 for 5 consecutive days. The warrants are exercisable at $1.19.
Extension of warrants, warrants extended							11,985,367
Warrants expense - vested warrants			$ 178,697									$ 6,027
Unamortized warrants expense			23,000	23,000		23,000
Intrinsic value of awards																																												7,500,000
Warrants issued											170,000						75,000		50,000	3,179,410	350,000	15,000		350,000	3,125	916,678	50,000	100,000	300,000	55,000	2,520,000	93,000	10,000	5,583,336		130,000	18,000	88,000	150,000	11,166,672	5,000,000
Fair value of warrants issued				$ 184,724	$ 111,370	$ 1,368,237					$ 232,374
Warrant Vesting terms											120,000 warrants vest equally over the next four quarters from the date of issuance. 50,000 warrants vest equally over the next two quarters from the date of issuance.